Understanding a BRCA positive diagnosis? This resource provides essential information for healthcare professionals on BRCA1/2 positive and BRCA mutation carrier status, covering clinical documentation best practices and medical coding guidelines related to BRCA mutations. Learn about managing patient care for individuals with a BRCA positive result.
Also known as
Genetic susceptibility to malignant neoplasm of breast
Indicates a person's increased risk of breast cancer due to genetic factors.
Genetic susceptibility to malignant neoplasm of ovary
Indicates a person's increased risk of ovarian cancer due to genetic factors.
Family history of malignant neoplasm of breast
Indicates a family history of breast cancer, increasing personal risk.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the BRCA status confirmed by genetic testing?
When to use each related code
| Description |
|---|
| Inherited mutation increasing breast/ovarian cancer risk. |
| Elevated breast cancer risk, no known BRCA mutation. |
| Variant of uncertain significance found in BRCA gene. |
Missing documentation specifying which BRCA gene (1 or 2) is affected, impacting accurate coding and reimbursement.
Lack of clear documentation confirming positive genetic test result for BRCA, leading to potential coding errors and compliance issues.
Inconsistent documentation between personal/family history of cancer and BRCA status, creating coding ambiguity and audit vulnerability.
Q: What are the most current NCCN guidelines for breast cancer screening and risk reduction strategies in patients with a BRCA1/2 positive result?
A: The National Comprehensive Cancer Network (NCCN) guidelines recommend enhanced screening and risk-reducing options for BRCA1/2 mutation carriers. These include more frequent breast MRI and mammogram screenings starting at a younger age, often beginning at age 25 or based on individual risk assessment. Risk-reducing medications, such as tamoxifen and raloxifene, are also options to consider discussing with patients. Prophylactic mastectomy and salpingo-oophorectomy are surgical options that significantly reduce the risk of breast and ovarian cancer. Explore how the latest NCCN guidelines incorporate personalized risk stratification based on factors such as family history and specific mutation type for tailored management of BRCA1/2 positive individuals.
Q: How do I effectively communicate BRCA1/2 positive results and management options with patients, including discussing potential surgical interventions like prophylactic mastectomy?
A: Communicating BRCA1/2 positive results requires a sensitive and comprehensive approach. Clearly explain the increased cancer risk associated with the specific mutation, and detail the range of screening and risk-reducing options, including enhanced surveillance with breast MRI and mammography, chemoprevention, and the possibility of prophylactic mastectomy and/or salpingo-oophorectomy. Provide tailored information based on the patient's age, family history, and personal preferences. Genetic counseling referral is essential for further risk assessment, family cascade testing, and emotional support. Consider implementing decision aids and resources to facilitate shared decision-making regarding complex choices like prophylactic surgery. Engage in open discussions about potential physical and psychological impacts of each option to empower patients to make informed decisions that align with their values and goals.
Patient presents for genetic counseling and risk assessment due to family history of breast cancer and ovarian cancer. Genetic testing was performed revealing a positive BRCA mutation, confirming the diagnosis of BRCA Positive. The patient is a confirmed BRCA mutation carrier, also referred to as BRCA1/2 positive. This significantly increases her lifetime risk of developing breast cancer, ovarian cancer, and potentially other cancers such as fallopian tube cancer, peritoneal cancer, and male breast cancer. Pre-test genetic counseling included discussion of potential results, implications for medical management, and options for risk reduction strategies. Post-test counseling addressed the specific BRCA mutation identified, personalized risk assessment, and recommendations for enhanced surveillance including breast MRI, mammogram, and pelvic ultrasounds. Prophylactic mastectomy and prophylactic oophorectomy were discussed as risk-reducing surgical options. Chemoprevention strategies were also reviewed. The patient will be referred to a high-risk breast clinic for ongoing monitoring and management. ICD-10 code Z15.01 (genetic susceptibility to malignant neoplasm of breast) and Z15.02 (genetic susceptibility to malignant neoplasm of ovary) are applicable. This documentation supports medical necessity for increased surveillance and consideration of risk-reducing interventions. Referral to support groups and psychological counseling was offered to address potential emotional impact. The patient demonstrates understanding of the diagnosis, implications, and management plan. Further genetic counseling sessions are scheduled to address family member testing and cascade testing recommendations.